These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 1316064)

  • 21. Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration.
    Baldwin DR; Wise R; Andrews JM; Gill M; Honeybourne D
    Respir Med; 1993 Nov; 87(8):595-601. PubMed ID: 8290743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Penetration into bone and joint tissues of rabbits and in vitro antibacterial activity of tosufloxacin].
    Yamashiro Y; Nunome M; Takahata M; Yasuda T
    Jpn J Antibiot; 1993 Jan; 46(1):31-5. PubMed ID: 8384277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disposable 1-day Acuvue contact lenses for the delivery of lomefloxacin to rabbits' eyes.
    Tian X; Iwatsu M; Kanai A
    CLAO J; 2001 Oct; 27(4):212-5. PubMed ID: 11725984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and safety of lomefloxacin following multiple doses.
    Hunt TL; Adams MA
    Diagn Microbiol Infect Dis; 1989; 12(2):181-7. PubMed ID: 2752716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lomefloxacin clinical pharmacokinetics.
    Freeman CD; Nicolau DP; Belliveau PP; Nightingale CH
    Clin Pharmacokinet; 1993 Jul; 25(1):6-19. PubMed ID: 8394795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent.
    Wise R; Johnson J; O'Sullivan N; Andrews JM; Imbimbo BP
    J Antimicrob Chemother; 1991 Dec; 28(6):905-9. PubMed ID: 1667783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Penetration of temafloxacin into body tissues and fluids.
    Sörgel F
    Clin Pharmacokinet; 1992; 22 Suppl 1():57-63. PubMed ID: 1319872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary disposition of lomefloxacin in patients with acute exacerbation of chronic obstructive pulmonary disease. A multiple-dose study.
    Cazzola M; Matera MG; Tufano MA; Catalanotti P; Polverino M; Cantoni V; Fici F; Sarlo F; Rossi F
    J Chemother; 2001 Aug; 13(4):407-12. PubMed ID: 11589484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative penetration of lomefloxacin and other quinolones into human phagocytes.
    Perea EJ; García I; Pascual A
    Am J Med; 1992 Apr; 92(4A):48S-51S. PubMed ID: 1316071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses.
    Kavi J; Stone J; Andrews JM; Ashby JP; Wise R
    Eur J Clin Microbiol Infect Dis; 1989 Feb; 8(2):168-70. PubMed ID: 2498102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylaxis in transurethral surgery: oral lomefloxacin versus intravenous cefuroxime.
    Martín-Luengo F; Fontana L; Rico JL; Tomás-Ros M; Murcia A; Romero A
    Methods Find Exp Clin Pharmacol; 1993; 15(1):57-9. PubMed ID: 8386794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Lemofloxacin: antimicrobial ability and clinico-pharmacokinetic basis for use in urogenital infections].
    Iakovlev SV
    Urologiia; 2002; (1):11-4. PubMed ID: 11877963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatobiliary elimination of temafloxacin.
    Sörgel F; Granneman GR; Mahr G; Kujath P; Fabian W; Nickel P
    Clin Pharmacokinet; 1992; 22 Suppl 1():33-42. PubMed ID: 1319869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days.
    Gros I; Carbon C
    Antimicrob Agents Chemother; 1990 Jan; 34(1):150-2. PubMed ID: 2327750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal clearance of lomefloxacin is decreased by furosemide.
    Sudoh T; Fujimura A; Shiga T; Sasaki M; Harada K; Tateishi T; Ohashi K; Ebihara A
    Eur J Clin Pharmacol; 1994; 46(3):267-9. PubMed ID: 8070509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and safety of single oral doses of lomefloxacin.
    Morse IS
    Biopharm Drug Dispos; 1990; 11(6):543-51. PubMed ID: 2207304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of enrofloxacin in adult horses and concentration of the drug in serum, body fluids, and endometrial tissues after repeated intragastrically administered doses.
    Giguère S; Sweeney RW; Bélanger M
    Am J Vet Res; 1996 Jul; 57(7):1025-30. PubMed ID: 8807015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of age on the pharmacokinetics of temafloxacin.
    Granneman GR; Guay DR
    Am J Med; 1991 Dec; 91(6A):71S-75S. PubMed ID: 1662898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacokinetic study of sparfloxacin in patients receiving regular hemodialysis].
    Aoki N; Kouda Y; Yoshikawa H; Usuda Y
    Jpn J Antibiot; 1995 Aug; 48(8):999-1002. PubMed ID: 7474327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary tract infection prophylaxis in transurethral surgery: oral lomefloxacin versus parenteral cefuroxime.
    Charton M; Mombet A; Gattegno B
    Am J Med; 1992 Apr; 92(4A):118S-120S. PubMed ID: 1316060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.